FWP Inference Case Change Doesn't Impact Fundamental Thesis on Biogen (BIIB); RBC Keeps at 'Outperform'
Tweet Send to a Friend
RBC Capital is commenting on the Forward Pharma (NYSE: FWP), Biogen (Nasdaq: BIIB) inference case tdaoy. Oral argument is ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
